NO120734B - - Google Patents
Download PDFInfo
- Publication number
- NO120734B NO120734B NO0696/68A NO69668A NO120734B NO 120734 B NO120734 B NO 120734B NO 0696/68 A NO0696/68 A NO 0696/68A NO 69668 A NO69668 A NO 69668A NO 120734 B NO120734 B NO 120734B
- Authority
- NO
- Norway
- Prior art keywords
- rifamycin
- lower alkyl
- methanol
- hours
- derivatives
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 7
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 claims description 6
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- -1 3-methylaminocrotonic acid dimethylamide Chemical compound 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- YPMPTULBFPFSEQ-PLNGDYQASA-N ethyl (z)-3-aminobut-2-enoate Chemical compound CCOC(=O)\C=C(\C)N YPMPTULBFPFSEQ-PLNGDYQASA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- QAKYFFYZPIPLDN-PLNGDYQASA-N methyl (z)-3-(methylamino)but-2-enoate Chemical compound CN\C(C)=C/C(=O)OC QAKYFFYZPIPLDN-PLNGDYQASA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940109171 rifamycin sv Drugs 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9755/67A GB1172155A (en) | 1967-03-01 | 1967-03-01 | New Rifamycins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO120734B true NO120734B (el) | 1970-11-30 |
Family
ID=9878162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO0696/68A NO120734B (el) | 1967-03-01 | 1968-02-26 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US3625961A (el) |
| BE (1) | BE711546A (el) |
| CH (1) | CH482716A (el) |
| DE (1) | DE1695384A1 (el) |
| DK (1) | DK129198B (el) |
| ES (1) | ES351070A1 (el) |
| FI (1) | FI48275C (el) |
| FR (2) | FR1562297A (el) |
| GB (1) | GB1172155A (el) |
| IL (1) | IL29441A (el) |
| NL (1) | NL6802429A (el) |
| NO (1) | NO120734B (el) |
| SE (1) | SE337829B (el) |
| YU (1) | YU31945B (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523199A (en) * | 1976-05-28 | 1978-08-31 | Lepetit Spa | Rifamycin sv derivatives |
| GB1523198A (en) * | 1976-05-28 | 1978-08-31 | Lepetit Spa | Thiazolo-rifamycin derivatives |
| DD204925A5 (de) * | 1980-09-25 | 1983-12-14 | Ciba Geigy Ag | Verfahren zur herstellung eines 4-aminoimidazolo (4,5-c)rifamycins sv oder s |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1090115A (en) * | 1964-04-02 | 1967-11-08 | Lepetit Spa | Mannich bases of rifamycin sv |
-
1967
- 1967-03-01 GB GB9755/67A patent/GB1172155A/en not_active Expired
-
1968
- 1968-02-05 US US702796A patent/US3625961A/en not_active Expired - Lifetime
- 1968-02-08 IL IL29441A patent/IL29441A/en unknown
- 1968-02-17 DE DE19681695384 patent/DE1695384A1/de not_active Withdrawn
- 1968-02-20 NL NL6802429A patent/NL6802429A/xx unknown
- 1968-02-23 FI FI680478A patent/FI48275C/fi active
- 1968-02-23 CH CH265968A patent/CH482716A/fr not_active IP Right Cessation
- 1968-02-26 NO NO0696/68A patent/NO120734B/no unknown
- 1968-02-28 SE SE02567/68A patent/SE337829B/xx unknown
- 1968-02-28 DK DK78568AA patent/DK129198B/da not_active IP Right Cessation
- 1968-02-29 ES ES351070A patent/ES351070A1/es not_active Expired
- 1968-03-01 YU YU0486/68A patent/YU31945B/xx unknown
- 1968-03-01 BE BE711546D patent/BE711546A/xx not_active IP Right Cessation
- 1968-03-01 FR FR1562297D patent/FR1562297A/fr not_active Expired
- 1968-05-28 FR FR153157A patent/FR7891M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL29441A (en) | 1971-05-26 |
| GB1172155A (en) | 1969-11-26 |
| DK129198C (el) | 1975-03-03 |
| DE1695384A1 (de) | 1972-04-13 |
| FR1562297A (el) | 1969-04-04 |
| FI48275C (fi) | 1974-08-12 |
| US3625961A (en) | 1971-12-07 |
| NL6802429A (el) | 1968-09-02 |
| FI48275B (el) | 1974-04-30 |
| YU48668A (en) | 1973-08-31 |
| DK129198B (da) | 1974-09-09 |
| YU31945B (en) | 1974-02-28 |
| FR7891M (el) | 1970-05-04 |
| BE711546A (el) | 1968-07-15 |
| CH482716A (fr) | 1969-12-15 |
| SE337829B (el) | 1971-08-23 |
| ES351070A1 (es) | 1969-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0009425B1 (en) | Novel naphtyridine derivatives and pharmaceutical compositions containing them | |
| US3165531A (en) | 13-substituted-6-deoxytetracyclines and process utilizing the same | |
| IE51204B1 (en) | Imidazo-rifamycin derivatives | |
| Agui et al. | Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acids | |
| EP0116208A1 (en) | Mitomycin analogues | |
| MXPA06001645A (es) | Isotiazoloquinolonas y compuestos relacionados como agentes anti-infecciosos. | |
| US4105778A (en) | Fused γ-pyrone-2-carboxylic acid derivatives and process therefor | |
| Chen et al. | Structure-activity relationships of 6-(heterocyclyl) methylene penam sulfones; a new class of β-lactamase inhibitors | |
| Tatsuta et al. | The Total Synthesis of a Glycosidase Inhibitor, Nagstatin. | |
| Gan-Jun et al. | Anti-methicillin-resistant Staphylococcus aureus assay of azalomycin F5a and its derivatives | |
| EP0333176B1 (en) | Substituted benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same | |
| NO120734B (el) | ||
| US4108998A (en) | Furo[3,4-b]quinoline derivatives and pharmaceutical compositions and methods employing them | |
| CN112500381B (zh) | 去氢中美菊素c衍生物及其制备方法和用途 | |
| JPH04300892A (ja) | パートリシン誘導体 | |
| NO160080B (no) | Analogifremgangsmaate for fremstilling av en ny terapeutisk aktiv syn-isomer av en 3-vinyl-3-cefem-forbindelse og farmasoeytisk godtagbare salter og estere derav. | |
| UHR et al. | The Structure of Acetomycin Spectroscopic Characterization and X-Ray Analysis of a Bromo Derivative | |
| US3678051A (en) | Derivatives of 1,6-phenazinediol 5,10-dioxide | |
| EP0203795B1 (en) | Benzo [i,j] quinolizine-2-carboxylic acid derivatives, the salts and their hydrates, pharmaceutical compositions thereof, and process for preparing the same | |
| US3681331A (en) | 1-hydroxy-6-amino alkoxy-phenazine 5,10-dioxides | |
| ZA200400208B (en) | Lactone formulations and method of use | |
| US3700679A (en) | Nuclear substituted derivatives of 1-hydroxy-6-methoxyphenazine 5,10-dioxide | |
| US4372961A (en) | Derivatives of rifamycins, their preparation and pharmaceutical compositions thereof | |
| CA1250846A (en) | 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8- naphthyridine-3 carboxylic acid compounds | |
| US3937707A (en) | 6-substituted 1-phenazinol 5,10-dioxide derivatives |